1. Akiki M, Haddad FG, Kourie HR, Khaddage A, Smayra VT, Smayra VT. PD-L1: an unavoidable biomarker in advanced triple-negative breast cancer. Biomark Med. 2019;13(18):1539–41.
2. Music M, Prassas I, Diamandis EP. Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers? Crit Rev Clin Lab Sci. 2018;55(7):466–79.
3. Navas T, Fino K, Fung KL, Cutuli F, Kinders RJ, Sharma A, et al. A multiplex immunofluorescence assay to assess immune checkpoint inhibitor-targeted CD8 activation and tumor colocalization in FFPE tissues. J Clin Oncol. 2019;37(15_Suppl l):2629.
4. Castaneda CA, Castillo M, Aliaga K, Bernabe LA, Casavilca S, Sanchez J, et al. Level of tumor-infiltrating lymphocytes and density of infiltrating immune cells in different malignancies. Biomark Med. 2019;13(17):1481–91.
5. Kroeze LI, de Voer RM, Kamping EJ, von Rhein D, Jansen EAM, Hermsen MJW, et al. Evaluation of a hybrid capture-based pan-cancer panel for analysis of treatment stratifying oncogenic aberrations and processes. J Mol Diagn. 2020;22(6):757–69.